Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Anil K. Sood, MD
M.D. Anderson Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Md Anderson Cancer Center at Cooper-Voorhees
Voorhees Township, New Jersey, United States
- Ut Southwestern/simmons Cancer Center-Dallas
Dallas, Texas, United States
- M D Anderson Cancer Center
Houston, Texas, United States
- Md Anderson Regional Care Center-Katy
Houston, Texas, United States
- the Woman'S Hospital of Texas
Houston, Texas, United States
- Md Anderson Regional Care Center-Bay Area
Nassau Bay, Texas, United States
- Md Anderson Regional Care Center-Sugar Land
Sugar Land, Texas, United States
- Md Anderson Regional Care Center-the Woodlands
The Woodlands, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 May 2017
- Primary completion
- 27 Sept 2022
- Completion
- 27 Sept 2022
- Last update posted
- 13 Mar 2024
- Registered enrollment
- 9
- Registry id
- NCT02923739
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.